美股市场个股详情
NUVL Nuvalent
- 92.730
- +1.560+1.71%
收盘价 11/21 16:00 (美东)
- 95.490
- +2.760+2.98%
盘前 04:37 (美东)
65.89亿总市值-26570市盈率TTM
94.580最高价90.115最低价39.68万股成交量91.440今开91.170昨收3702.39万成交额0.97%换手率亏损市盈率(静)7105.26万总股本113.51052周最高5.88市净率37.82亿流通值61.01552周最低--股息TTM4078.73万流通股113.510历史最高--股息率TTM4.90%振幅7.090历史最低93.300平均价1股每手
关于Nuvalent公司
Nuvalent, Inc.是一家临床阶段的生物制药公司，专注于为癌症患者创造精确靶向治疗。其产品线包括ROS1 NSCLC、ALK NSCLC和HER2 NSCLC。
公司介绍
公司代码NUVL
公司名称Nuvalent
上市日期2021/07/29
发行价格17.00
成立日期2017
CEODr. James R. Porter, PhD
所属市场纳斯达克
员工数量92
年结日12-31
公司地址One Broadway,14th floor
城市Cambridge
省份马萨诸塞州
国家美国
邮编02142
电话1-857-357-7000
董事高管
- 姓名
- 职务
- 年薪
- Dr. Matthew Shair, PhD
- Director, Scientific Founder and Head Scientific Advisor
- 68.82万
- Dr. James R. Porter, PhD
- Director, Chief Executive Officer and President
- 937.69万
- Dr. Deborah Miller, J.D.,PhD
- Chief Legal Officer and Secretary
- --
- Darlene Noci, A.C.I.S.
- Chief Development Officer
- --
- Alexandra Balcom, M.B.A.
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- 354.16万
- Dr. Christopher D. Turner, M.D.
- Chief Medical Officer
- 360.32万
- Dr. Michael L. Meyers, M.D.,PhD
- Independent Director
- 49.44万
- Dr. Sapna Srivastava, PhD
- Independent Director
- 50.32万
- Dr. Emily Drabant Conley, PhD
- Independent Director
- 49.59万
- Dr. Cameron A. Wheeler, PhD
- Independent Director
- 49.95万
- Dr. Andrew A. F. Hack, M.D.,PhD
- Independent Director
- 49.57万
- Anna Protopapas
- Independent Director
- 52.32万
- Dr. D. Gary Gilliland, M.D.,PhD
- Independent Director
- 49.57万
- Dr. Joseph Pearlberg, M.D.,PhD
- Independent Director
- 49.40万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据